Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 2/20 | 0.41 |
| ▸ | LSS | P48449 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 3/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | PLG | P00747 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.33 |
| ▸ | CLK1 | P49759 | 1/20 | 0.32 |
| ▸ | CLK2 | P49760 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.32 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.32 |
| ▸ | HIPK3 | Q9H422 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL942185 | 0.86 | LMNA (0.33) | HRH3SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL942881 | 0.81 | HRH3 (0.36) | HRH3KCNH2SMN1; SMN2 | |
| SCHEMBL23917278 | 0.68 | QDPR (0.57) | QDPRLSSHTR6DRD3HRH3 | |
| SCHEMBL14704043 | 0.67 | DRD3 (0.39) | DRD3HRH3ESR2 | |
| SCHEMBL13394781 | 0.66 | DRD3 (0.38) | DRD3HRH3ESR2SMN1; SMN2 | |
| SCHEMBL14701604 | 0.65 | NPC1 (0.34) | SMN1; SMN2 | |
| SCHEMBL20346931 | 0.65 | ATM (0.38) | HRH3SMN1; SMN2 | |
| SCHEMBL23057248 | 0.64 | QDPR (0.52) | QDPRLSSHTR6DRD3PLG | |
| SCHEMBL23349335 | 0.63 | NPC1 (0.33) | SMN1; SMN2 | |
| SCHEMBL24221667 | 0.63 | NPC1 (0.33) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524705-B2 | 2-oxo-2-(2-phenyl-5,6,7,8-tetrahydro-indolizin-3-yl)-acetamide derivatives and related compounds as antifungal agents | F2G LIMITED BRITISH BODY CORPORATE (GB) | 2013-09-03 | — | — | US | disclosed |
| US-20110009390-A1 | 2-OXO-2- (2-PHENYL-5,6,7,8-TETRAHYDRO-INDOLIZIN-3-YL) -ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ANTIFUNGAL AGENTS | F2G LIMITED (GB) | 2011-01-13 | — | — | US | disclosed |
| EP-2173749-B1 | 2-OXO-2- (2-PHENYL-5,6,7,8-TETRAHYDRO-INDOLIZIN-3-YL) -ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ANTIFUNGAL AGENTS | F2G LTD (GB) | 2011-01-12 | — | — | EP | disclosed |
| EP-2173749-A1 | 2-OXO-2- (2-PHENYL-5,6,7,8-TETRAHYDRO-INDOLIZIN-3-YL) -ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ANTIFUNGAL AGENTS | F2G Limited (GB) | 2010-04-14 | — | — | EP | disclosed |
| WO-2008145963-A1 | 2-OXO-2- (2-PHENYL-5,6,7,8-TETRAHYDRO-INDOLIZIN-3-YL) -ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ANTIFUNGAL AGENTS | F2G LIMITED (GB) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009390-A1 | 2-OXO-2- (2-PHENYL-5,6,7,8-TETRAHYDRO-INDOLIZIN-3-YL) -ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ANTIFUNGAL AGENTS | NAT1, FOXM1, CYP51A1 | QDPR 589/4885LSS 358/4885HTR6 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.